Data on minimal residual disease (MRD) 
Abstract:
Data on minimal residual disease (MRD) monitoring in acute promyelocytic leukemia (APL) is available only in the context of conventional ATRA plus chemotherapy regimens. It is recognized that the kinetics of leukemia clearance is different with the use of arsenic trioxide (ATO) in the treatment of APL. We undertook a prospective peripheral blood reverse transcriptase polymerase chain reaction (RT-PCR) based MRD monitoring study on patients with APL treated with a single agent ATO regimen. 151 patients were enrolled in this study. A positive RT-PCR reading at the end of induction therapy was significantly associated on a multivariate analysis with an increased risk of relapse (RR=4.9; P-value=0.034). None of the good risk patients who were RT-PCR negative at the end of induction relapsed. Majority of the relapses (91%) happened within three years of completion of treatment. Post achievement of molecular remission the current MRD monitoring strategy was able to predict relapse in 60% of cases with an overall sensitivity and specificity of 60% and 93.2% respectively. High risk group patients and those that remain RT-PCR positive at the end of induction are likely to benefit from serial MRD monitoring by RT-PCR for a period of 3 years from completion of therapy.
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Introduction:
Treatment of acute promyelocytic leukemia (APL) with a conventional all-trans retinoic acid (ATRA) combined with chemotherapy has resulted in significant improvements in the clinical outcome 1 . Major causes of failure with a conventional ATRA plus chemotherapy schedule includes early mortality (10-30%) related to a hemorrhagic diathesis 2 and subsequent relapse (10-30% each) 3, 4 . Monitoring minimal residual disease (MRD) by detection of the PML-RARA fusion transcript, in the peripheral blood or bone marrow, using a conventional polymerase chain reaction (RT-PCR) has been shown to be an effective strategy to predict relapse 5, 6 . . Extrapolation of data generated from ATRA plus chemotherapy regimens may potentially not be valid when applied to regimens that use ATO in upfront therapy.
At our center we undertook a prospective MRD detection study in patients treated with a single agent ATO based regimen as reported by us previously 9 .
Material and Methods:

Patients and samples:
From March, 2000 till April, 2010, newly diagnosed APL patients treated with a single agent ATO regimen (as reported previously 9, 14 ) were enrolled for prospective MRD detection at our centre, after getting written and informed consent. For enrollment it was mandatory that in addition to conventional diagnostic criteria the patient should have had a positive RT-PCR for the PML-RARA fusion transcripts at diagnosis.
Sample time points for MRD monitoring:
Peripheral blood samples were to be collected for RT-PCR at diagnosis, at the end of induction, beginning of consolidation, every 3 months during maintenance. After completion of maintenance therapy peripheral blood samples were scheduled to be collected once in three months for the first two years and once in 6 months for the next three years (Figure 1 ). RT-PCR analysis was done prospectively for all cases enrolled in this study.
We retrospectively checked the PML-RARA transcript levels by RQ-PCR on samples at molecular relapse and one sample point before the molecular relapse / frank hematological relapse (within 3-4 months prior to documented relapse). The values generated in these cases were compared with twice the number of age and WBC count at presentation matched controls that were greater than 2 years from completion of therapy and remained in continuous complete hematological (CHR) and molecular remission (CRm) by RT-PCR.
Amplification of PML-RARA fusion transcripts:
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Cytogenetic analysis and Determination of FLT3 mutation status:
The details of the methods and reporting criteria for cytogenetic (CTG) analysis and the methods for molecular detection of FLT3 mutations is given in Appendix 4 and 5 respectively.
Definition of outcomes:
Definition of hematological complete remission (CHR), overall survival (OS), event free survival (EFS), molecular remission (CRm) and molecular relapse was as reported earlier by us for this regimen 14 . Relapse free survival (RFS) was calculated from time of achieving CR to the patient's last follow up or an event defined as hematological relapse only.
Statistical Methods:
The 
Results:
Patient accrual and baseline characteristics:
Between March, 2000 and April, 2010, 173 patients with PML-RARA+ APL were eligible to be enrolled for this study. Patients who died prior to starting treatment (n=1), during induction (n=18), those who were discharged against medical advise (n=2) or were primary refractory (n=1) were excluded from this study. The remaining 151 patients were enrolled after getting written and informed consent. The baseline characteristics and there impact on RFS of the patients enrolled is summarized in Table 1 .
Peripheral blood samples for MRD detection:
RT-PCR was done prospectively on all patients. A total 1764 peripheral blood samples was collected from 151 patients (median=12; range: 5-19) from a possible maximum of 2348, based on the planned schedule for MRD monitoring, for an overall compliance rate of 75.12%. Figure 1 summarizes the RT-PCR collection time points in relationship to the protocol used (as reported previously 9, 14 ) and the compliance rate at each of these time points.
Response and relapses following therapy:
By definition, for this analysis, only patients who were documented to have 
Kinetics of PML-RARA clearance with an ATO based induction regimen by RT-PCR:
The RT-PCR done at end of induction, beginning of consolidation and at the beginning of the maintenance was assessed for evaluating the clearance of PML-RARA 
Prediction of relapse based on RT-PCR clearance post initiation of therapy:
At the end of induction 90 patients (63.82%) remained RT-PCR positive. These patients on a univariate analysis had an increased risk of relapse compared to those that were negative at this time point (RR=4.8; 95% CI=1.66-13.67; P-value=0.004). On a step wise forward multivariate analysis after adjusting for parameters that on a univariate analysis had a significant or trend to significance for increased risk of relapse or were well established risk factors for relapse (Table 2) 
Kinetics of PML-RARA clearance by RQ-PCR in an ATO based regimen:
Unlike RT-PCR, the RQ-PCR was not done prospectively. Retrospective RQ-PCR analysis was only done on patients who had relapsed and a cohort of age and WBC count at diagnosis matched cases (controls) that were in continuous complete remission for greater than two years from completion of maintenance (n=28 and 35 respectively; based on availability of banked cDNA). Table 3 
Role of sequential RQ-PCR monitoring in predicting molecular relapse prior to hematological relapse:
Retrospectively RQ-PCR was done, based on availability of banked cDNA, on most hematological relapse cases (n=25) on a sample collected in the 3 to 4 months prior to a documented hematological relapse. RQ-PCR was also done on most of the set of age and WBC at presentation matched controls (table 3) who remained in continuous complete remission for greater than two years from completion of maintenance (n=35). From the data reported here it would be reasonable in future to consider stopping MRD monitoring for all good risk group patient who were in CRm at the end of induction therapy even with this low intensity regimen, though it is important to note that in this series less than 10% of the entire cohort would fall into this group. For those who are RT-PCR positive at the end of induction and for all high risk cases MRD monitoring should probably be continued for at least 3 years post completion of maintenance therapy. 
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this strategy would not have significantly improved our ability to predict relapse. As suggested and demonstrated in an earlier study the use of a bone marrow sample and the RARA-PML transcript detection could improve the sensitivity, though the absolute number of patients who would benefit over and above having done a qualitative RT-PCR for PML-RARA transcripts alone is not clear 6 . In our setting (developing country) and we suspect in many other resource constrained environments and also from a patients perspective these are not practical options. In our own analysis an additional 6 cases would have had a hematological relapse predicted by the use of an RQ-PCR over that achieved by RT-PCR alone which would take successful prediction from 10% to 13.9%
of the entire cohort. This degree of increment in sensitivity would not make this a cost effective option for us. Further, we are reassured by our own experience that even in the event of a frank hematological relapse treatment with an ATO based induction and consolidation followed by an autologous SCT in CRm can achieve a cure in up to 70% of cases 22 .
In conclusion MRD detection with an ATO based regimen demonstrates significant differences in kinetics of leukemia clearance and ability to predict relapse. To improve the sensitivity of MRD detection by peripheral blood monitoring a practical option that could potentially be considered is to increase the frequency of testing to once in two months for the first two years post completion of therapy when the majority of hematological relapses happen. This remains to be validated prospectively.
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